Data as of Jul 25, 2026 · Based on 2,718,867 AI responses across 9,511 prompts · See how Parse measures this
Arrowhead Pharmaceuticalsarrowheadpharma.com · Low evidenceArrowhead Pharmaceuticals uses its targeted RNAi molecule platform, TRiM™, to silence disease-causing genes. The company is advancing plozasiran (formerly ARO-APOC3) in Phase 3 trials for severe hypertriglyceridemia, aiming to have 20 products in clinical trials or on the market by 2025.
Parse Score